Subject to update: 

• CAR T cell therapies in hematological malignancies
• CAR and TCR targets
• Engineered T cell therapy for solid tumours
• Non-viral vectors and transposons
• Allogeneic/universal donor cells
• Rare, autoimmune and infectious diseases as cell therapy targets
• New approaches in lymphocyte engineering
• Regulatory Perspectives and Requirements in Advanced Therapies